# Feasibility Study of Exenatide by Continuous Subcutaneous Infusion

> **NCT01857895** · PHASE1 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 10 (actual)

## Conditions studied

- Obesity

## Interventions

- **DRUG:** Exenatide

## Key facts

- **NCT ID:** NCT01857895
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-05-16
- **Primary completion:** 2013-11-01
- **Final completion:** 2013-11-01
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2017-10-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01857895

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01857895, "Feasibility Study of Exenatide by Continuous Subcutaneous Infusion". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01857895. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*